검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Gene Modified T Cells |
Overview Company | Calimmune, Inc. |
Overview Modality | CGT |
Overview Target | Prostate Cancer |
Overview Indication | Prostate Cancer |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting multiple tumor antigen to avoid tumor antigen |
MoA Biomarker | biomarkers to optimize selection of patients who most likely would benefit from ACT, using combination therap |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Ready or not, here they come: a practical guide to adoptive T-cell therapies for solid tumors for medical oncologists.. Adoptive cell therapies (ACTs) include chimeric antigen receptors (CARs), bispecific T-cell engagers (BiTES), tumor-infiltrating lymphocytes, and T-cell receptor (TCR) gene-modified T-cells. ACTs have significantly improved patient outcomes associated with hematologic malignancie… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 92.9% |
Clinical ORR | 92.9% |
Clinical Result source | ClinicalTrials.gov NCT03310619 |
Clinical Data Tier / Score | A · 37 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Gene Modified T Cells |
Overview Company | Calimmune, Inc. |
Overview Modality | CGT |
Overview Target | Prostate Cancer |
Overview Indication | Prostate Cancer |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting multiple tumor antigen to avoid tumor antigen |
MoA Biomarker | biomarkers to optimize selection of patients who most likely would benefit from ACT, using combination therap |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Ready or not, here they come: a practical guide to adoptive T-cell therapies for solid tumors for medical oncologists.. Adoptive cell therapies (ACTs) include chimeric antigen receptors (CARs), bispecific T-cell engagers (BiTES), tumor-infiltrating lymphocytes, and T-cell receptor (TCR) gene-modified T-cells. ACTs have significantly improved patient outcomes associated with hematologic malignancie… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 92.9% |
Clinical ORR | 92.9% |
Clinical Result source | ClinicalTrials.gov NCT03310619 |
Clinical Data Tier / Score | A · 37 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교